NIPH Clinical Trials Search

UMIN ID: UMIN000016738

Registered date:08/03/2015

Zinc L-carnosine complex polaprezinc for pica and polydipsia

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedPica and polydipsia
Date of first enrollment2015/03/09
Target sample size20
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Polaprezinc 75 or 150 mg/day per os for 24 weeks.


Primary OutcomeFrequency of pica
Secondary OutcomeSeverity of polydipsia assessed by diurnal weight gain and blood concentration of sodium Serum concentrations of BDNF and mature BDNF

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Malignant tumor 2) Chronic renal failure (estimated glomerular filtration rate, eGFR <45) 3) Other severe diseases 4) Terminal phase of an illness 5) History of taking polaprezinc or other zinc supplementation

Related Information


public contact
Name Kensaku Sakae
Address 1089 Tsurugasone, Yashio-shi, Saitama 340-0802, Japan Japan 340-0802
Telephone 048-996-3034
Affiliation Keieikai Yashio Hospital Department of psychiatry
scientific contact
Name Kensaku Sakae
Address 3-25-8 Nishishimbashi, Minato-ku, Tokyo Japan
Telephone 03-3433-1111(ext.2266)
Affiliation The Jikei University School of Medicine Department of Public Health and Environmental Medicine